Research programme: camelid nanobody-based bispecific NK cell engagers - Sauvie
Latest Information Update: 27 Oct 2022
At a glance
- Originator Rutgers
- Class Antineoplastics; Immunotherapies; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer